- Location
hyperphosphatemia
"-
The US FDA Has Approved Vifor Pharma's Hyperphosphatemia Drug Velphoro
Dec 3, 2013The US Food and Drug Administration (FDA) has approved Vifor Pharma's hyperphosphatemia drug Velphoro for the control of serum phosphorus levels in patients with Chronic Kidney Disease (CKD) on dialysis. Approval of Velphor, which is an ...
Tags: Drug, phosphate binder
-
OPKO Health Has Signed a Definitive Agreement to Acquire Cytochroma
Jan 14, 2013Multinational pharmaceutical and diagnostics company OPKO Health has signed a definitive agreement to acquire Cytochroma. Under the purchase, OPKO intends to include Cytochroma's Replidea and Alpharen, which are in Phase 3 clinical trials ...
Tags: OPKO Health, Cytochroma, CKD, pharmaceutical
-
Japan Tobacco Has Filed a New Drug Application for The Marketing Approval
Jan 9, 2013Japan Tobacco (JT), Keryx Biopharmaceuticals' Japanese partner, has filed a new drug application (NDA) for the marketing approval of Ferric Citrate (Zerenex) in Japan for the treatment of hyperphosphatemia in chronic kidney disease (CKD) ...
Tags: Ferric Citrate, Tobacco, CKD, Pharmaceutical
-
FDA Approved Perrigo's ANDA for Calcium Acetate Capsules
Jan 1, 2013The US Food and Drug Administration (FDA) has approved Perrigo's abbreviated new drug application (ANDA) for calcium acetate capsules. The generic equivalent of Phoslo Gelcaps are used to treat hyperphosphatemia in patients with end stage ...
Tags: FDA, Perrigo ANDA, calcium acetate capsules
-
Astellas Pharma Received Japanese Marketing Approval for Kiklin Capsules
Dec 5, 2012Astellas Pharma has received Japanese marketing approval for Kiklin capsules to treat hyperphosphatemia in patients on dialysis with chronic kidney disease. Kiklin capsules, amine-functional polymers, bind to phosphate in the ...
Tags: Kiklin capsules, hyperphosphatemia, chronic kidney disease
-
Astellas Pharma Has Launched Kiklin Capsules 250mg
Nov 30, 2012Astellas Pharma has launched Kiklin capsules 250mg (generic name:Bixalomar) in Japan for the treatment of hyperphosphatemia in patients on dialysis with chronic kidney disease. Kiklin Capsules bind to phosphate in the gastrointestinal ...
Related Products
-
USP 98% High Quality Lanthanum Carbonate CAS 587-26-8 Powder for Hyperphosphatemia in Patients with End-Stage Renal Disease
-
Anti-Hyperphosphatemia Sevelamer Carbonate Raw Powder CAS 845273-93-0 API Sevelamer Carbonate
-
Pharmaceutical Ingredient Calcium Acetate Manufacturer Treat Hyperphosphatemia Phosphorus Binder.
